Clinical Trial Update: Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase 1 study of autologous lymphocytes with cyclophosphamide and aldesleukin for metastatic melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Aldesleukin (Proleukin) (aldesleukin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Therapeutic Autologous Lymphocytes

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Stage IV Melanoma | Phase 1 | Status: TERMINATED